

MARKET RELEASE

MedAdvisor signs \$2.6M deal with major US biotech

Expands US revenue with new health programs

Melbourne, Australia, 26 November, 2020 - Medtech company, MedAdvisor Limited (ASX: MDR) reports its subsidiary, Adheris LLC, has today signed a one-year deal with a major US biopharmaceutical company worth USD \$1.89 million (AUD \$2.6 million). This is a renewal of a program run in FY20. This deal is with a US-listed company with a market capitalisation exceeding USD \$70 billion.

The health program uses several of the Group's product offerings in the US and covers a highly complex disease area. The program will leverage the data and analytics platform to target patient awareness and adherence across the Adheris network.

MedAdvisor US President, John Ciccio commented on the deal saying: "MedAdvisor's strong US performance continues as we start to see the results of the ramp in investment in the US market. Our clients are impressed by the technology offerings we're able to provide, reaching 1 in 2 Americans to help improve medication adherence."

In accordance with the terms of the commercial agreement, MedAdvisor cannot disclose the name of the company for which these programs will be run. The agreement is for one-year with standard termination and commercial confidentiality provisions. There are no conditions precedent and all material terms have been disclosed.

After successfully completing the acquisition of Adheris this month, the company's sales performance has already exceeded MedAdvisor's initial expectations for H2 and is up 74% year-on-year for the four months ended 31 October. The first four months of H2 revenue for FY20 was USD \$10.9 million compared to USD \$6.3 million in FY19. While the first months of FY20 sales have already exceeded H2 FY19 total sales of USD \$10.4 million. MedAdvisor's H2 revenue forecast for Adheris was USD \$13.8 million.

MedAdvisor also recently announced it had extended its health program deal with a top 10 global pharmaceutical company. The program is for CY21 and Adheris' FY21 budget for the program is USD \$800K (AUD \$1.1M) based on estimates of patient reach.

This document has been authorised for release by Carlo Campiciano, MedAdvisor Company Secretary.

- ENDS -

For more information:

Simon Glover
Chief Financial Officer
corporate@medadvisor.com.au
+61 3 9095 3036

Alex Beashel
Corporate Communications
ab@alexbeashel.com
+61 466 308 667

About MedAdvisor

MedAdvisor is a world-class medication management platform that empowers users to more simply manage their medication and improve adherence. MedAdvisor's highly automated and intuitive software system connects users to tools and education materials from their local/preferred pharmacy. In Australia, MedAdvisor has connected over 1.6 million users through more than 60% of Australian pharmacies and a network of thousands of GPs. MedAdvisor has recently partnered with HMS in the US, Zuellig Pharma in Asia and launched into the UK on track to become one of the largest players in the global digital adherence market. In 2018 and 2020, MedAdvisor was recognised in the AFR Fast 100. Visit: mymedadvisor.com/investors